Strategic acquisition, joint venture, and licensing deal
Our attorneys recently advised longtime client Novartis Pharmaceuticals on the intellectual property-related aspects of a series of strategic deals totaling $30 billion, including the landmark acquisition of GlaxoSmithKline’s oncology unit for up to $16 billion. In exchange, GSK will acquire Novartis’ vaccine business, excluding its flu products, for up to $7.1 billion, plus royalties. The two companies will also form a joint venture in consumer healthcare products, combining Novartis’ over-the-counter pharmaceuticals business with GSK’s consumer operations.
In addition to the GSK deals, Novartis announced the sale of its animal health unit to Eli Lilly & Co. for $5.2 billion. All of these transactions are designed to strategically overhaul Novartis’ operations in order to focus on its most valuable businesses moving forward.